Skip to main content
LYSOGENE logo

LYSOGENE — Investor Relations & Filings

Ticker · LYS ISIN · FR0013233475 LEI · 969500T64RILK1RD0852 PA Professional, scientific and technical activities
Open in API
Filings indexed 254 across all filing types
Latest filing 2019-04-23 Earnings Release
Country FR France
Listing PA LYS

About LYSOGENE

https://www.lysogene.com

Lysogene was a clinical-stage biotechnology company that specialized in the research and development of gene therapies for rare, inherited neurodegenerative diseases affecting the central nervous system (CNS). The company's approach focused on delivering a functional copy of a deficient gene directly to the brain to address the root cause of the targeted disorder. Its pipeline included investigational treatments for lysosomal storage diseases such as Sanfilippo syndrome type A (MPS IIIA) and GM1 gangliosidosis. Following clinical and financial challenges, the company initiated judicial liquidation proceedings in 2023.

Recent filings

Filing Released Lang Actions
Quarterly financial reporting / First quarter financial report
Earnings Release Classification · 1% confidence The document explicitly states it reports 'first quarter 2019 financial information' and provides key figures like net cash position (€35.2 million) and revenues (€5 million) as of March 31, 2019. This content structure—a brief announcement highlighting key financial metrics for a recent short period (Q1)—is characteristic of an Earnings Release (ER). It is not the full, comprehensive report (which would be an IR) nor is it a transcript (CT) or a presentation (IP). Given the short length (2462 chars) and focus on immediate results, ER is the most appropriate classification. Q1 2019
2019-04-23 English
Information financière trimestrielle / Information financière du premier trimestre
Earnings Release Classification · 1% confidence The document is titled "Communiqué de Presse" and explicitly announces "Information financière du 1er trimestre 2019" (First Quarter 2019 financial information), detailing cash position and revenue for the period ending March 31, 2019. This content—a brief announcement of key quarterly financial highlights—perfectly matches the definition of an Earnings Release (ER). Although it mentions IFRS standards, it is a press release summarizing results, not the comprehensive Interim Report (IR) itself. Given its short length (2747 chars) and press release format, ER is the most appropriate classification. Q1 2019
2019-04-23 French
Informations privilégiées / Information sur chiffre d’affaires annuel
Earnings Release Classification · 1% confidence The document is titled "Lysogene annonce ses résultats annuels 2018 et fait le point sur ses opérations" (Lysogene announces its 2018 annual results and provides an update on its operations) and is explicitly labeled as a "Communiqué de Presse" (Press Release). It contains key financial highlights for the year 2018, including revenue, operating result, net result, and cash position, along with operational updates (clinical trials, partnerships). This format, summarizing annual financial performance in a press release format, strongly indicates an Earnings Release (ER). Although it covers annual results, it is a summary announcement rather than the full, detailed 10-K filing. The document also mentions the upcoming "Document de Référence 2018" (which is the French equivalent of the 10-K/Annual Report) on April 30, 2019, confirming this document is the preliminary announcement of results, fitting the ER definition. FY 2018
2019-04-11 French
Inside Information / Information on annual revenues
Earnings Release Classification · 1% confidence The document is explicitly titled "Lysogene Reports Full Year 2018 Financial Results and Provides Operational Update" and is presented as a "Press release." It contains selected financial information for the year ended December 31, 2018, including revenues, operating loss, and net income, along with operational highlights. This structure—a press release summarizing annual financial performance—is characteristic of an Earnings Release (ER). While it covers the full year (like a 10-K), the format is a brief announcement of results rather than the comprehensive, audited 10-K filing itself. It is not a transcript (CT), a formal audit report (AR), or a detailed management discussion (MDA), but rather the initial public announcement of the results. The document also mentions upcoming events, including the release of the 'Reference Document 2018' (which might contain the 10-K equivalent), confirming this document is the preliminary results announcement. FY 2018
2019-04-11 English
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Earnings Release Classification · 1% confidence The document is a joint press release from Lysogene and Sarepta Therapeutics announcing that the first patient has been dosed in the AAVance Phase 2/3 clinical trial for LYS-SAF302 for MPS IIIA. This announcement details clinical trial progress, scientific background, management commentary, and financial implications (milestone payments). This type of announcement, focusing on operational and clinical milestones rather than comprehensive financial results (like a 10-K or IR) or just executive compensation (DEF 14A), is characteristic of an Earnings Release (ER) or a general press release announcing significant corporate/clinical news. Since it is a detailed announcement of a clinical milestone and partnership update, it fits best under the 'Earnings Release' category (ER) as it often accompanies or precedes formal earnings reports, or serves as a major operational update that investors track closely. It is not a full financial report (10-K, IR), a transcript (CT), or a proxy statement (DEF 14A). Given the context of major operational news, ER is the most appropriate fit among the provided options, although RNS (Regulatory Filings) is a possibility if it were purely a regulatory filing notice. However, the structure strongly suggests an 'Earnings Release' style announcement. FY 2019
2019-02-14 English
Communicated under the obligation to provide permanent information / Information on annual revenues
Earnings Release Classification · 1% confidence The document is explicitly titled 'Press Release' and reports 'fourth quarter 2018 financial information' including cash position and revenues as of December 31, 2018. This format, providing key financial highlights for a specific period (Q4 2018) immediately following the period end, is characteristic of an Earnings Release (ER). It is not a comprehensive report (like 10-K or IR) nor a transcript (CT). Given its brevity and focus on initial results announcement, ER is the most appropriate classification. Q4 2018
2019-02-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.